ReviewMedicinal research reviews2018
Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.
Review in Medicinal research reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic influence of lymphatic endothelium-specific hyaluronan receptor 1 in cancer: A systematic review.Cancer science · 2022Pooled it
- Corneal lymphangiogenesis as a potential target in dry eye disease - a systematic review.Survey of ophthalmologyPooled it
- Bioengineered Lymphatic Vessels in Synthetic Matrices to Study Breast Cancer Cell Functions.Advanced healthcare materials · 2026Article
- Targeting glycolytic reprogramming by tsRNA-0032 for treating pathological lymphangiogenesis.Cell death & disease · 2025Article
- Epsin Endocytic Adaptor Proteins in Angiogenic and Lymphangiogenic Signaling.Cold Spring Harbor perspectives in medicine · 2024Review
- Scopoletin: a review of its pharmacology, pharmacokinetics, and toxicity.Frontiers in pharmacology · 2024Review
- Modeling lymphangiogenesis: Pairing in vitro and in vivo metrics.Microcirculation (New York, N.Y. : 1994) · 2023Review
- Lymphangiogenesis Guidance Mechanisms and Therapeutic Implications in Pathological States of the Cornea.Cells · 2023Review
- Metastasis prevention: targeting causes and roots.Clinical & experimental metastasis · 2022Review
- KRAS mutations as essential promoters of lymphangiogenesis via extracellular vesicles in pancreatic cancer.The Journal of clinical investigation · 2022Article
- Hepatic lymphatic vascular system in health and disease.Journal of hepatology · 2022Review
- The lymphatic vasculature: An active and dynamic player in cancer progression.Medicinal research reviews · 2022Review
- Effect of Angiogenesis and Lymphangiogenesis in Diesel Exhaust Particles Inhalation in Mouse Model of LPS Induced Acute Otitis Media.Frontiers in cellular and infection microbiology · 2022Article
- Lymphatic Vessel Regression and Its Therapeutic Applications: Learning From Principles of Blood Vessel Regression.Frontiers in physiology · 2022Review
- Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics.EMBO molecular medicine · 2021Article
- Review
- Article
- Targeting tumor vascularization: promising strategies for vascular normalization.Journal of cancer research and clinical oncology · 2021Review
- 3,4-Difluorobenzocurcumin Inhibits Vegfc-Vegfr3-Erk Signalling to Block Developmental Lymphangiogenesis in Zebrafish.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Expression levels of VEGF-C and VEGFR-3 in renal cell carcinoma and their association with lymph node metastasis.Experimental and therapeutic medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
In recent years, lymphangiogenesis, the process of lymphatic vessel formation from existing lymph vessels, has been demonstrated to have a significant role in diverse pathologies, including cancer metastasis, organ graft rejection, and lymphedema. Our understanding of the mechanisms of lymphangiogenesis has advanced on the heels of studies demonstrating vascular endothelial growth factor C as a central pro-lymphangiogenic regulator and others identifying multiple lymphatic endothelial biomarkers. Despite these breakthroughs and a growing appreciation of the signaling events that govern the lymphangiogenic process, there are no FDA-approved drugs that target lymphangiogenesis. In this review, we reflect on the lessons available from the development of antiangiogenic therapies (26 FDA-approved drugs to date), review current lymphangiogenesis research including nanotechnology in therapeutic drug delivery and imaging, and discuss molecules in the lymphangiogenic pathway that are promising therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.